Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643793
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-09-27
Brief Title:
Evaluation of Irinotecan Liposome II Combined With 5-FU LV and Bevacizumab for mCRC
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Evaluation of Irinotecan Liposome II Combined With 5-fluorouracil Leucovorin and Bevacizumab for Second-lineThird-line Treatment of Metastatic Colorectal Cancer mCRC a Prospective and Exploratory Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To observe and evaluate the efficacy and safety of irinotecan liposome II combined with 5-fluorouracil5-FU calcium leucovorinLV and bevacizumab in the treatment of metastatic colorectal cancer
Detailed Description:
Subjects enter the screening period after being fully informed and signing an informed consent form The screening period for the study is 28 days After completing the screening inspection and evaluation the selected subjects receive irinotecan liposome II combined with 5-FULV and bevacizumab treatment a total of 4 anti-tumor treatment cycles were observed After the 4 cycles of treatment the next step of treatment was jointly decided after the evaluation of the researcher and the consideration of the patients personal treatment wishes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None